Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.

Autor: Charych DH; Nektar Therapeutics, San Francisco, California. dcharych@nektar.com., Hoch U; Nektar Therapeutics, San Francisco, California., Langowski JL; Nektar Therapeutics, San Francisco, California., Lee SR; Nektar Therapeutics, San Francisco, California., Addepalli MK; Nektar Therapeutics, San Francisco, California., Kirk PB; Nektar Therapeutics, San Francisco, California., Sheng D; Nektar Therapeutics, San Francisco, California., Liu X; Nektar Therapeutics, San Francisco, California., Sims PW; Nektar Therapeutics, San Francisco, California., VanderVeen LA; Nektar Therapeutics, San Francisco, California., Ali CF; Nektar Therapeutics, San Francisco, California., Chang TK; Nektar Therapeutics, San Francisco, California., Konakova M; Nektar Therapeutics, San Francisco, California., Pena RL; Nektar Therapeutics, San Francisco, California., Kanhere RS; Nektar Therapeutics, San Francisco, California., Kirksey YM; Nektar Therapeutics, San Francisco, California., Ji C; Nektar Therapeutics, San Francisco, California., Wang Y; Nektar Therapeutics, San Francisco, California., Huang J; Nektar Therapeutics, San Francisco, California., Sweeney TD; Nektar Therapeutics, San Francisco, California., Kantak SS; Nektar Therapeutics, San Francisco, California., Doberstein SK; Nektar Therapeutics, San Francisco, California.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2016 Feb 01; Vol. 22 (3), pp. 680-90.